Exact Sciences
EXAS
#1154
Rank
$19.17 B
Marketcap
$101.06
Share price
-0.07%
Change (1 day)
61.41%
Change (1 year)
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.

Exact Sciences (EXAS) - Total debt

Total debt on the balance sheet as of September 2025 : $2.52 Billion USD

According to Exact Sciences's latest financial reports the company's total debt is $2.52 Billion USD. A companyโ€™s total debt is the sum of all current and non-current debts.

Exact Sciences - Total debt on balance sheet (from 2009 to 2025)

Total debt by year

Year Total debt Change
2024-12-31$2.75 B7.83%
2023-12-31$2.55 B4.41%
2022-12-31$2.44 B2.72%
2021-12-31$2.38 B2.21%
2020-12-31$2.33 B144.04%
2019-12-31$0.95 B38.56%
2018-12-31$0.68 B15385.31%
2017-12-31$4.45 M-18.97%
2016-12-31$5.49 M-8.69%
2015-12-31$6.01 M102.29%
2014-12-31$2.97 M-31.88%
2013-12-31$4.36 M113.6%
2012-12-31$2.04 M104.4%
2011-12-31$1 M0%
2010-12-31$1 M-49.7%
2009-12-31$1.98 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Myriad Genetics
MYGN
$0.21 B-91.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Antares Pharma
ATRS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Veracyte
VCYT
$40.45 M-98.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Biocept
BIOC
$11.59 M-99.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
$25.53 B 912.60%๐Ÿ‡ซ๐Ÿ‡ท France